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ABSTRACT
Albendazole is an anti-helminthic drug that has been shown to exhibit anti-cancer 
properties, however its activity in head and neck squamous cell cancer (HNSCC) was 
unknown. Using a series of in vitro assays, we assessed the ability of albendazole 
to inhibit proliferation in 20 HNSCC cell lines across a range of albendazole doses 
(1 nM–10 μM). Cell lines that responded to treatment were further examined for 
cell death, inhibition of migration and cell cycle arrest. Thirteen of fourteen human 
papillomavirus-negative HNSCC cell lines responded to albendazole, with an average 
IC50 of 152 nM. In contrast, only 3 of 6 human papillomavirus-positive HNSCC cell lines 
responded. Albendazole treatment resulted in apoptosis, inhibition of cell migration, 
cell cycle arrest in the G2/M phase and altered tubulin distribution. Normal control 
cells were not measurably affected by any dose tested. This study indicates that 
albendazole acts to inhibit the proliferation of human papillomavirus-negative HNSCC 
cell lines and thus warrants further study as a potential chemotherapeutic agent for 
patients suffering from head and neck cancer.
INTRODUCTION
Head and neck cancer is the 6th most common 
cancer diagnosis worldwide, with a reported annual 
incidence of over 550,000 cases [1]. Although tobacco 
and alcohol consumption are recognized as the two 
main risk factors for the development of head and neck 
squamous cell cancer (HNSCC), a subset of the tumours 
are associated with human papillomavirus (HPV) 
infection and viral oncogene expression. There has been 
considerable focus on the management of this HPV-
positive disease due to the dramatic rise of incidence in 
patients that are typically younger in age and healthier 
[2]. The favorable survival outcomes in the HPV-positive 
patients has led to significant efforts to de-intensify their 
treatment [3]. In contrast, patients with HPV-negative 
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disease make up a large portion of HNSCC (~40–60%) and 
experience markedly poorer survival outcomes relative to 
those that are HPV-positive [4, 5]. There is a critical need 
to identify novel therapeutics for patients with classic risk 
factors (smoking and drinking) that lead to HPV-negative 
HNSCC disease. 
Albendazole is a benzimidazole carbamate with an 
extensive history of safe and routine use in both humans 
and animals to eliminate parasitic worms [6, 7]. The anti-
helminthic ability of albendazole and other drugs of the 
benzimidazole class has been primarily attributed to their 
tubulin binding capacity, resulting in de-polymerization 
and cell-cycle arrest in nematodes [8]. The ability of 
benzimidazoles to inhibit microtubule polymerization 
has led to investigation of their anti-cancer potential in 
melanoma, ovarian, colorectal and hepatocellular cancer 
models [9–12]. In addition to disrupting tubulin assembly 
and causing cell cycle arrest in cancer cells, initial studies 
demonstrated that this drug significantly reduced both 
VEGF and HIF-1α activity and inhibited angiogenesis 
[13, 14]. Albendazole has also been recognized as a 
radiosensitizer in melanoma and small-cell lung cancer 
models [9].
Here we demonstrate that albendazole markedly 
reduces HNSCC cell-growth, with preferential activity in 
HPV-negative cell lines. We further show that albendazole 
can cause cell death and apoptosis, reduce cellular migration, 
induce cell-cycle arrest, and alter tubulin polymerization 
within in vitro HNSCC experimental models. 
RESULTS
Albendazole inhibited HNSCC cell line 
proliferation, with preferential activity in  
HPV-negative cell lines
We tested 20 HNSCC cell lines (14 HPV-negative 
and 6 HPV-positive) with a range of albendazole doses 
(1 nM–10 μM) to calculate half-maximal inhibitory 
concentration (IC50) values. Cells that did not reach 50% 
viability relative to the control were considered non-
susceptible in the concentration range tested, and were 
assigned an IC50 value of 10 μM (maximum dose tested) 
for further analyses. Albendazole inhibited growth in 13 of 
14 (93%) HPV-negative cell lines at the tested doses when 
compared to the untreated cells (Figure 1A). In contrast, 
only 3 of 6 (50%) HPV-positive cell lines exhibited 
reduced growth in response to albendazole treatment at 
the doses tested (Figure 1A). HPV-negative cell lines had 
lower mean IC50 values compared to the HPV-positive 
HNSCC lines (p = 0.03, Figure 1B). Three normal cell 
lines were also treated with albendazole and none reached 
an IC50 in the dose range tested, confirming the specificity 
of albendazole for cancer cell lines.
Figure 1: Albendazole inhibited the cell growth of HNSCC cell lines, with preferential activity in HPV-negative cell 
lines. (A) HPV-negative, HPV-positive and normal cell lines were tested against increasing doses of albendazole in order to calculate IC50 
values. Cell lines that did not reach 50% viability at the maximum dose (10 µM) are denoted as NS (not susceptible). (B) Mean potency 
of albendazole for HPV-negative, HPV-positive and normal cell lines. Cell lines that did not reach IC50 were assigned a value of 10 μM 
(highest concentration tested) for statistical analysis. This potency trend suggests that albendazole demonstrates preferential activity in 
HPV-negative cell lines (unpaired t-test; p < 0.05). Error bars reflect standard error, *p < 0.05 and ***p < 0.001. 
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Albendazole treatment caused cell death and 
apoptosis in the susceptible cell lines
To measure the effect of albendazole on cell health, 
we performed live/dead assays. A significant increase in 
the frequency of cell death was measured after the addition 
of albendazole in the susceptible cell lines (Figure 2A). 
This observation was true regardless of whether the cells 
were HPV-positive or HPV-negative. Statistical analysis 
(paired t-test) showed that albendazole caused a significant 
increase in the percent of dead cells within susceptible 
(Cal33 p = 0.028 and SCC47 p = 0.0006) cell lines, but no 
significant changes in the non-susceptible (HSC2 p = 0.75, 
93-VU-147T p = 0.56) and normal (WI38 p = 0.53) cell 
lines. Thus, the ability of albendazole to induce cell death 
is fully concordant with the reduction in cell proliferation 
described above. 
Based on previous studies, we hypothesized that 
the drug-induced cell death may involve apoptosis [9]. 
Immunoblotting with an anti-PARP antibody demonstrated 
that albendazole treatment induced partial cleavage of 
PARP in a dose dependent manner (Figure 2B). Weak 
PARP cleavage was visible starting at 0.5 uM and 
increased as the dose was further escalated (Figure 2B).
Albendazole reduced cell migration in the 
susceptible HNSCC cell lines
In an effort to observe the effect of albendazole on 
cell migration, we performed scratch assays in 4 HPV-
negative and 4 HPV-positive HNSCC cell lines (Figure 3). 
Albendazole treatment significantly reduced the rate 
of migration in the cell lines considered susceptible by 
the cell proliferation studies (Cal33 p < 0.0001, Cal27 
p < 0.0001, JHU011 p < 0.0001, SCC47 p = 0.0039, 
SCC154 p < 0.0001). This effect was generally observed 
at doses at or greater than 0.5 µM and was independent 
of HPV status (Figure 3). In contrast, non-susceptible 
cell lines did not respond with a significant change in the 
migration rate to doses of albendazole as high as 1 μM 
(p > 0.05 in HSC2, SCC2 and 93-VU-147T). 
Albendazole blocked cell cycle progression
To determine how the cell cycle was being affected 
by albendazole treatment, we performed flow cytometry 
analysis. Flow cytometry indicated that albendazole 
treatment altered the distribution of cells in various 
phases of the cell-cycle (Figure 4). In all cell lines tested, 
albendazole resulted in the accumulation of cells in the 
G2/M phase of the cell cycle. The average increase in 
the frequency of G2/M phase cells following treatment 
with albendazole was significantly less in the normal 
WI38 cell line than Cal33 (unpaired t-test, p < 0.0001) or 
SCC47 (unpaired t-test, p < 0.0001) cell lines. We also 
observed a reduced proportion of S phase cells in the 
HNSCC cell lines, which further supports the hypothesis 
that albendazole acts to inhibit cell proliferation. 
Albendazole altered cellular tubulin distribution
Based on the known ability of albendazole to disrupt 
tubulin assembly, we examined α-tubulin distribution 
within Cal33 cells in response to treatment with various 
Figure 2: Albendazole caused cell death and apoptosis. (A) Live/dead assays were performed with Cal33, HSC2, SCC47, 93-VU-
147T and WI38 cell samples that were exposed to vehicle (DMSO-only) or 0.5 μM of albendazole (ABZ) for 24 hours (four replicates per 
treatment). Albendazole treatment significantly increased the percentage of dead cells in susceptible cell lines (Cal33 and SCC47; paired 
t-test, p = 0.026 and p < 0.001 respectively), but yielded insignificant changes in HSC2, 93-VU-147T and WI38 cell lines. “(S)” marks 
the susceptible, and “(R)” marks the non-susceptible cell lines by IC50 analysis. Error bars show standard error, *p < 0.05 and **p < 0.01. 
(B) Cal33 cells were exposed to vehicle (DMSO-only), 0.5 μM or 1 μM ABZ for 24 hours, and immunoblotted for PARP. Staurosporine 
(St.) treatment was used as a positive control for apoptosis. Presence of cleaved PARP (c-PARP) at 1 μM albendazole treatment suggested 
that apoptosis was involved in cell death. 
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doses of albendazole. Visualization of α-tubulin distribution 
within Cal33 cells by indirect immunofluorescence 
revealed a dose-dependent change in tubulin distribution 
and alteration of the tubulin assembly (Figure 5). 
Specifically, treatment with just 0.1 μM albendazole caused 
a slightly increased concentration of tubulin around the 
nuclei as compared to the normal cytoplasmic distribution 
of α-tubulin in the vehicle (DMSO-only) treated cells. 
Tubulin distribution became progressively perinuclear at 
higher drug concentrations. Indeed, at higher albendazole 
doses of 0.5 μM and 1 μM there is a distinct absence 
of ordinary cytoplasmic tubulin distribution, with the 
appearance of concentric clumping of tubulin around the 
nuclei and heavy nuclear staining.
DISCUSSION
The development of targeted cancer therapies based 
on personalized medicine has been considered by many to 
be the future of cancer treatment. One consequence of the 
huge development and testing costs for these treatments 
has been a rapid and economically unsustainable increase 
in the cost of new cancer drugs [15]. As an attractive 
alternative solution, repurposing the large arsenal of 
existing approved, non-cancer drugs for cancer treatment 
has become the focus of intense investigation [16]. 
Albendazole is an approved anti-parasitic drug with 
an extensive history of safe and routine use in humans 
since it was first approved in 1982 [6, 7]. Due to the 
accumulating evidence that this drug may have potent 
growth inhibitory effect on multiple types of cancer cells 
[8–12], we decided to investigate albendazole for its 
effects on head and neck cancer cells.
Albendazole had a potent anti-proliferative effect in 
our panel of HNSCC cell lines, and we demonstrate that it 
has preferential activity against HPV-negative lines. Growth 
inhibition was accompanied by increased cell death in all 
drug sensitive cell lines. Cell death was likely mediated by 
Figure 3: Albendazole impaired cell migration. Scratch assays were performed with 4 HPV-positive and 4 HPV-negative cell lines, 
exposed to various concentrations of albendazole, and imaged at 0, 2, 5, 8, and 12 hours post-treatment. Linear regression analysis was used 
to calculate the rate of growth (in μm/hour). Albendazole significantly reduced the rate of cell migration in cell lines that were susceptible in 
IC50 analysis, and led to no significant changes in migration rate in the non-susceptible cell lines (ANCOVA analysis, ns = not significant, 
**p < 0.01, ***p < 0.001). “(S)” marks the susceptible, and “(R)” marks the non-susceptible cell lines by IC50 analysis. Error bars 
represent standard error.
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increased apoptosis, based on an increased level of PARP 
cleavage. As the prognosis for patients with HPV-negative 
tumors is much worse than for HPV-positive cancers [4], 
the improved activity of albendazole against HPV-negative 
cell lines has important clinical ramifications. The reduced 
effectiveness of albendazole in HPV-positive HNSCC cell 
lines may be due to an HPV-related inhibition of apoptosis 
[17]. Further work is needed to elucidate the mechanisms 
Figure 4: Albendazole induced cell cycle arrest at G2/M phase. Cal33 (HPV-negative), SCC47 (HPV-positive) and WI38 
(normal) cells were exposed to vehicle (DMSO-only) or 0.5 μM albendazole (ABZ) for 24 hours (3 replicates per treatment, ± standard 
error is shown). BrdU and PI staining were carried out prior to flow cytometry analysis. “(S)” marks cells lines susceptible, and “(R)” marks 
cell lines not susceptible to albendazole in IC50 analysis. *p < 0.05, **p < 0.01, ***p < 0.001, and NS = not significant.
Figure 5: Dose-dependent disruption in the distribution of α-tubulin following exposure to albendazole. Experimental 
treatments included vehicle (DMSO), 0.1 μM, 0.5 μM aornd 1 μM albendazole for 24 hours. α-tubulin was visualized using 
immunofluorescence (green) and nuclei were stained with DAPI (blue). 40x fluorescence microscopy was used to assess changes in cellular 
morphology and tubulin distribution. 
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underlying the differential treatment responses in HPV-
positive and negative cell lines. 
Consistent with previous studies in other cancer 
types, flow cytometry analysis demonstrated that 
albendazole treatment arrested HNSCC cells in the G2/M 
phase. This may result, at least in part from albendazole’s 
known ability to inhibit tubulin polymerization [18], which 
is essential for mitosis. We confirmed that albendazole 
treatment dramatically altered the appearance and 
distribution of tubulin in HNSCC cells. 
The observation that albendazole triggers an arrest 
in the G2/M stage of the cell cycle is intriguing, as 
different cell cycle phases are associated with sensitivity 
to radiotherapy, with the impact of radiation maximized 
during the G2/M phase of the cycle [19]. Investigations 
with small-cell lung cancer and melanoma cells have 
demonstrated that albendazole and radiation can act in 
synergy to inhibit cancer cell growth [9]. These findings 
similarly suggest the potential application of albendazole 
as a radiosensitizer in HNSCC treatment. 
The routine use of the benzimidazoles in humans 
for control of infectious diseases highlights their safety 
and clinical applicability. However, the low aqueous 
solubility and bioavailability of benzimidazoles is a 
potential limiting factor in the use of these drugs as cancer 
therapeutics [20–22]. Investigations with intravenous 
delivery of the albendazole, nanoparticle assemblies 
and solid dispersion techniques offer potential solutions 
to increase the absorbance and plasma concentration of 
albendazole [23–27]. Further research is required to assess 
the response of head and neck cancer cells to these drug 
delivery methods.
In conclusion, albendazole has shown strong 
potential as a chemotherapeutic agent with high potency 
against HNSCC cell lines, particularly in the HPV-
negative subset. We have shown that albendazole can 
cause cell death through activation of apoptosis, initiation 
of cell-cycle arrest and alteration of tubulin distribution 
in vitro in HNSCC cell line models, collectively 
highlighting its multi-faceted ability to control the growth 
of these cancer cells. 
MATERIALS AND METHODS 
Reagents
Albendazole was obtained from Selleck Chemicals®. 
Albendazole was dissolved in dimethyl sulfoxide (DMSO) 
at a concentration of 10 mM to create a stock solution and 
stored at –80°C.
Cell cultures
Human WI38, IMR90, HSC2 and primary oral 
epithelial cells (hPOE; Abm Inc.) were grown in EMEM 
(Wisent) supplemented with 10% fetal bovine serum 
(FBS; Wisent), penicillin (100 IU/mL; Invitrogen) and 
streptomycin (100 μg/mL; Invitrogen). Detroit 562, Cal27, 
SCC9, FaDu, SCC15 were purchased from ATCC. RF37B 
and RF22A were a kind gift of Dr. Robert Ferris (University 
of Pittsburgh), UPCI:SCC090 and UPCI:SCC154 
were obtained from Dr. Suzanne Gollin (University of 
Pittsburgh), PCI6B (University of Pittsburgh), HMS001 
(a gift of Dr. James Rocco, Harvard Medical School), 
JHU011 (Johns Hopkins University), JHU006 (Johns 
Hopkins University), 93-VU-147T gift of Dr. Johan de 
Winter, VU Medical Center, Amsterdam, and SCC61 
were a gift of Dr. Wendell Yarborough, Yale University. 
Most HNSCC cell lines and were grown in DMEM/F12 
(Wisent) supplemented with 10% fetal bovine serum 
(FBS; GIBCO), penicillin (100 IU/mL; Invitrogen) and 
streptomycin (100 μg/mL; Invitrogen). Cal33 cells were 
grown in DMEM (Wisent) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; GIBCO), penicillin 
(100 IU/mL; Invitrogen) and streptomycin (100 μg/mL; 
Invitrogen). BICR56 cells were grown in DMEM (Wisent) 
supplemented with 10% fetal bovine serum (FBS; Wisent), 
penicillin (100 IU/mL; Wisent), streptomycin (100 μg/mL; 
Wisent), hydrocortisone (0.4μg/ml, Wisent) and glutamine 
(2 mM, Wisent). Cells were incubated at 37°C and 5% CO2. 
Drug potency assay
Cell lines were seeded in 96-well plates at 3000 
cells/well. 24 hours later, albendazole was added in a 
concentration series of 1, 3, 10, 30, 100, 300, 1000, 3000 
and 10000 nM. Cells were exposed to drug for 72 hours 
before assessing potency. For each drug concentration, 
three replicates were carried out per cell line. Cell viability 
was measured indirectly using the PrestoBlue® Reagent 
(Thermofisher Scientific). To calculate the half-maximal 
inhibitory concentration (IC50) value for each cell line, 
the media alone (blank) was subtracted from the Relative 
Fluorescence Unit (RFU) measures of each replicate to 
account for the background signal. Normalized RFUs of the 
drug-treated replicates were calculated as a percentage of the 
mean RFU of the vehicle control (DMSO-only) treatment 
replicates. IC50 values, defined as the concentration at which 
the normalized RFU reached 50%, were calculated by non-
linear regression (Prism® 7 Graphpad Software, Inc). Only 
cell lines that dropped below 50% normalized RFU within 
the dose range tested were considered to be substantially 
affected by drug. An unpaired t-test was used to assess the 
significance of the differences in IC50 values between HPV-
positive and HPV-negative cell lines.
Live/dead assay
Cal33, HSC2, SCC47, 93-VU-147T and WI38 
cell lines were seeded in 60 mm plates at a density of 
100,000 cells/mL. Twenty-four hours later, samples were 
treated with either vehicle control (DMSO) or albendazole 
(500 nM). Four replicates of each treatment were used. 
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Plates were incubated at 37°C for 24 hours. Samples were 
trypsinized, and resuspended in media. For each replicate, 
10 μL resuspended cells were mixed with Trypan blue 
(Sigma-Aldrich) at a 1:1 ratio, allowed to incubate for 
10 minutes, and placed on a hemocytometer for imaging 
under brightfield microscopy. The ratio of live:dead cells 
was then calculated for each plate. Two readings of each 
sample were performed. Statistical significance was 
determined using a paired t-test as DMSO-only and drug-
treated replicate readings were done in pairs. 
Western blotting
Cal33 cells were treated with DMSO, 500 nM or 
1 μM albendazole for 24 hours. As a positive control for 
apoptosis, Cal33 cells were treated with 1μM staurosporin 
(Selleck Chemicals) for 4 hours. PARP primary antibody 
(Genetex Inc., cat. GTX100573), was administered 
according to manufacturer recommendations. Actin levels 
were detected using a rabbit anti-actin primary antibody 
(Sigma-Aldrich, cat. A2066), and the same secondary 
antibody (G-anti-R) and detection method as previously 
noted. Western blot image is presented as scanned. 
Scratch assay
Cells were seeded and allowed to grow in 6-well 
plates until a confluent monolayer was formed. Each well 
was then scratched across using a P1000 pipette tip. Media 
was aspirated and the wells were washed twice using PBS. 
Media (2 mL) with the drug concentration of choice was 
added to each well. Treatment groups included DMSO-
only, 100 nM, 500 nM, or 1 μM albendazole. Regions of 
the scratch to be imaged were then marked. Plates were 
immediately imaged under a 4× objective to calculate 
the initial distance between the two edges of scratch in 
each well. This served as the 0 hour control. Cells were 
then incubated at 37°C and imaging was repeated at 2, 
5, 8 and 12 hours. The distance of migration of the edge 
was measured (μm) at 10 points for each image. Rate of 
migration (μm per hour) and standard error calculated for 
each treatment using Prism® 7. Statistical analysis was 
done through ANCOVA analysis in the Prism® 7 software. 
Flow cytometry 
To determine the potential effects of albendazole 
on cell cycle, we treated Cal33, SCC47 and WI38 cells 
with DMSO-only and 0.5 μM of albendazole for 24 hours. 
Three replicates of each treatment were prepared. Cell 
proliferation labeling reagent (5-bromo-2′-deoxyuridine 
and 5-fluoro-2′-deoxyuridine) (GE Healthcare, cat. 
RPN201) was added to the media and cultures were 
incubated for 2 hours prior to harvesting. Cells were 
trypsinized, resuspended in media and washed 3 times with 
PBS. 95% Ethanol was used to fix cells. Cells were exposed 
to 2N HCL/0.5% Triton X-100 and then 0.1 M NaB4O7 
for permeabilization. Mouse anti-BrdU primary antibody 
(1:50, BD Biosciences lot. 347580) and FITC-conjugated 
horse anti-mouse secondary antibody (1:25, Vector 
Laboratories cat. FI-2000) were added respectively, and 
incubated for 30 minutes per step, at room temperature 
and protected from light. Cells were then collected and 
resuspended in propidium iodide (PI;10 mg/mL) 
and RNase A (0.25 mg/mL, Bioshop Canada Inc., cat. 
RNA675), and incubated overnight at 4°C. To remove 
cell aggregates, cell suspensions were passed through 
cell strainers (Falcon® Corning Science Ref. 352235). 
Flow cytometry analysis was then performed (Beckman 
Coulter Inc, CytomicsTM FC500). Unpaired t-test statistical 
analyses were performed for all of the comparisons. 
Immunofluorescence
Cal33 cells were seeded and grown on glass 
coverslips and exposed to DMSO-only, 100 nM, 500 nM 
or 1 μM albendazole treatments for 24 hours. Three 
replicates of each treatment were prepared. Cells were 
fixed to the coverslips using 100% methanol (pre-chilled 
at –20°C). Samples were blocked using 5% normal 
donkey serum (Wisent) in PBS. Cells were then incubated 
for 1 hour with α-tubulin primary antibody (1:50, Cell 
Signaling Technology Cat. ID 2125) at room temperature, 
then washed extensively with PBS. Alexa Fluor® 488 goat 
anti-rabbit IgG secondary antibody (1:1000, Molecular 
Probes, Inc.A-11008) was added to each slide and then 
incubated in the dark for 60 minutes. DAPI (Molecular 
Probes, Inc., 30 nM) was used for nuclear staining. Images 
were obtained under 40x magnification using an Olympus 
Provis AX70 microscope. 
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